Theranostic Fluorescent Probes

Chemical Reviews, Год журнала: 2024, Номер 124(5), С. 2699 - 2804

Опубликована: Фев. 29, 2024

The ability to gain spatiotemporal information, and in some cases achieve control, the context of drug delivery makes theranostic fluorescent probes an attractive intensely investigated research topic. This interest is reflected steep rise publications on topic that have appeared over past decade. Theranostic probes, their various incarnations, generally comprise a fluorophore linked masked drug, which released as result certain stimuli, with both intrinsic extrinsic stimuli being reported. release then signaled by emergence signal. Importantly, use appropriate fluorophores has enabled not only this emerging fluorescence marker for but also provided modalities useful photodynamic, photothermal, sonodynamic therapeutic applications. In review we highlight recent work particular focus are activated tumor microenvironments. We summarize efforts develop other applications, such neurodegenerative diseases antibacterials. celebrates diversity designs reported date, from discrete small-molecule systems nanomaterials. Our aim provide insights into potential clinical impact still-emerging direction.

Язык: Английский

---

Liquid biopsy for human cancer: cancer screening, monitoring, and treatment

MedComm, Год журнала: 2024, Номер 5(6)

Опубликована: Май 28, 2024

Currently, tumor treatment modalities such as immunotherapy and targeted therapy have more stringent requirements for obtaining growth information require accurate easy-to-operate detection methods. Compared with traditional tissue biopsy, liquid biopsy is a novel, minimally invasive, real-time tool detecting directly or indirectly released by tumors in human body fluids, which suitable the of new modalities. Liquid has not been widely used clinical practice, there are fewer reviews related applications. This review summarizes applications components (e.g., circulating cells, DNA, extracellular vesicles, etc.) tumorigenesis progression. includes development process techniques biopsies, early screening tumors, detection, guiding therapeutic strategies (liquid biopsy-based personalized medicine prediction response). Finally, current challenges future directions proposed. In sum, this will inspire researchers to use technology promote realization individualized therapy, improve efficacy provide better options patients.

Язык: Английский

---

Beyond blood: Advancing the frontiers of liquid biopsy in oncology and personalized medicine

Cancer Science, Год журнала: 2024, Номер 115(4), С. 1060 - 1072

Опубликована: Фев. 3, 2024

Abstract Liquid biopsy is emerging as a pivotal tool in precision oncology, offering noninvasive and comprehensive approach to cancer diagnostics management. By harnessing biofluids such blood, urine, saliva, cerebrospinal fluid, pleural effusions, this technique profiles key biomarkers including circulating tumor DNA, cells, microRNAs, extracellular vesicles. This review discusses the extended scope of liquid biopsy, highlighting its indispensable role enhancing patient outcomes through early detection, continuous monitoring, tailored therapy. While advantages are notable, we also address challenges, emphasizing necessity for precision, cost‐effectiveness, standardized methodologies broader application. The future trajectory set expand reach personalized medicine, fueled by technological advancements collaborative research.

Язык: Английский

---

Recent advancement in the detection of potential cancer biomarkers using the nanomaterial integrated electrochemical sensing technique: a detailed review

Materials Advances, Год журнала: 2024, Номер 5(2), С. 475 - 503

Опубликована: Янв. 1, 2024

Graphical representation of the overview lung and oral cancer from detection to medical treatment.

Язык: Английский

---

Emerging biomarkers for non-invasive diagnosis and treatment of cancer: a systematic review

Frontiers in Oncology, Год журнала: 2024, Номер 14

Опубликована: Июль 26, 2024

Cancer remains a global health challenge, necessitating continuous advancements in diagnostic and treatment strategies. This review focuses on the utility of non-invasive biomarkers cancer diagnosis treatment, their role early detection, disease monitoring, personalized therapeutic interventions. Through systematic literature, we identified 45 relevant studies that highlight potential these across various types, such as breast, prostate, lung, colorectal cancers. The discussed include liquid biopsies, epigenetic markers, non-coding RNAs, exosomal cargo, metabolites. Notably, particularly those based circulating tumour DNA (ctDNA), have emerged most promising method for early, detection due to ability provide comprehensive genetic information from easily accessible blood samples. demonstrates how can facilitate accurate subtyping, tailored strategies, thereby improving patient outcomes. It underscores transformative oncology, highlighting application enhancing survival rates, precision care.

Язык: Английский

---

Liquid Biopsy in the Clinical Management of Cancers

International Journal of Molecular Sciences, Год журнала: 2024, Номер 25(16), С. 8594 - 8594

Опубликована: Авг. 6, 2024

Liquid biopsy, a noninvasive diagnosis that examines circulating tumor components in body fluids, is increasingly used cancer management. An overview of relevant literature emphasizes the current state liquid biopsy applications care. Biomarkers particularly DNA (ctDNA), RNAs (ctRNA), cells (CTCs), extracellular vesicles (EVs), and other components, offer promising opportunities for early diagnosis, treatment selection, monitoring, disease assessment. The implementation precision medicine has shown significant potential various types, including lung cancer, colorectal breast prostate cancer. Advances genomic molecular technologies such as next-generation sequencing (NGS) digital polymerase chain reaction (dPCR) have expanded utility enabling detection somatic variants actionable alterations tumors. also demonstrated predicting responses, monitoring minimal residual (MRD), assessing heterogeneity. Nevertheless, standardizing techniques, interpreting results, integrating them into clinical routine remain challenges. Despite these challenges, implications management, offering dynamic approach to understanding biology guiding personalized strategies.

Язык: Английский

---

Advancements in Circulating Tumor Cell Research: Bridging Biology and Clinical Applications

Cancers, Год журнала: 2024, Номер 16(6), С. 1213 - 1213

Опубликована: Март 20, 2024

Circulating tumor cells (CTCs) are released from the primary and metastatic intravasate into blood or lymphatic vessels, where they transported to distant sites act as seeds that initiate cancer metastases development of further lesions. Recent advances in CTC research have shown their relevance prognostic markers for early disease detection, predictive biomarkers relapse, response medical intervention therapy. The rapidly evolving landscape biology has opened new avenues understanding progression, metastasis, treatment response. Additionally, translating these findings clinical applications holds promise improving diagnostics, prognosis, personalized therapeutic strategies. This review discusses significance CTCs associated challenges. We explore recent developments detection characterization implications practice.

Язык: Английский

---

Atomic force microscopy combined with microfluidics for label-free sorting and automated nanomechanics of circulating tumor cells in liquid biopsy

Nanoscale, Год журнала: 2025, Номер unknown

Опубликована: Янв. 1, 2025

This work combines deep learning image recognition-assisted atomic force microscopy with contraction–expansion microfluidics to achieve label-free sorting and automated nanomechanics of circulating tumor cells for cancer liquid biopsy.

Язык: Английский

---

A scoping review of factors influencing the implementation of liquid biopsy for cancer care

Journal of Experimental & Clinical Cancer Research, Год журнала: 2025, Номер 44(1)

Опубликована: Фев. 12, 2025

Abstract Background Liquid biopsy (LB) offers a promising, minimally invasive alternative to traditional tissue biopsies in cancer care, enabling real-time monitoring and personalized treatment. Despite its potential, the routine implementation of LB clinical practice faces significant challenges. This scoping review examines barriers facilitators influencing liquid into standard care. Methods Four academic databases (PubMed, Scopus, Embase, Web Science) were systematically searched without language restrictions. We included peer-reviewed articles that published between January 2019 March 2024 focused on care or described implementation. Data relevant objective, including key article characteristics; implementation; recommendations for advancement optimisation; extracted analysed using thematic visual network analyses. Results The majority narrative (84%), with most from China (24.2%) United States (20%). Thematic analysis identified four main categories their associated care: (1) Laboratory personnel requirements; (2) Disease specificity; (3) Biomarker-based biopsy; (4) Policy regulation. concentrated pre-analytical phase, highlighting lack standardization technologies outcomes. Conclusions Through implementation, we present an integrated tool designed encourage testing methods guidelines field.

Язык: Английский

---

Retinoblastoma: Aqueous humor liquid biopsy

Taiwan Journal of Ophthalmology, Год журнала: 2025, Номер 15(1), С. 55 - 61

Опубликована: Янв. 1, 2025

Abstract: Advances in retinoblastoma (RB) therapy have led to significantly improved ocular preservation rates, consequently limiting access histologic and genomic information traditionally obtained from enucleated eyes. Moreover, specimens often represents heavily pretreated, refractory disease. The introduction of aqueous humor (AH) biopsy marks a significant milestone oncology, offering vivo , real-time tumoral data that can be collected at diagnosis repeatedly throughout treatment. This liquid has detected RB1 gene mutations deletions identified potential clinical biomarkers, such as amplification the 6p chromosomal region MYCN gene. In addition, monitoring trends tumor fraction provides dynamic insights into disease progression. While further research is required validate these findings larger populations uncover new scientific community shown growing interest this novel approach. AH safe reproducible procedure supports precision oncology by providing tumor-specific for each patient eye.

Язык: Английский

---